Peiman Hematti, MD

Position title: Professor, Medicine / Pediatrics / Surgery / Biomedical Engineering

Email: pxh@medicine.wisc.edu

Phone: 608-265-0106

Organ System/Disease Focus:
Hematopoietic (blood) system; Treatment of hematological malignancies, Transplant Immunology, Graft versus host disease
Aligned Research Focus:
Hematopoietic stem cell biology
Peiman Hematti headshot

Pubmed

News Releases:
More information:
Research Description:

Peiman Hematti, MD is Professor of Medicine in section of Hematology/Oncology, UW-Madison School of Medicine and Public Health, with joint appointments in departments of pediatrics, surgery and biomedical engineering. He is director of Clinical Hematopoietic Cell Processing Laboratory, and medical director of Apheresis and Hematopoietic Cell Collection facility at University of Wisconsin-Madison, overseeing bone marrow and stem cell collections, and clinical processing procedures for hematopoietic cell transplantation or other cellular therapy applications at UW-Madison Hospital and Clinics. In addition to participating in clinical care of bone marrow stem cell transplant patients Dr. Hematti is a co-investigator on many novel cellular therapy clinical trials. His clinical research interest is in the prevention and treatment of graft versus host disease and other post-transplant immunological complications, novel cellular therapies for cancer treatment, and use of bone marrow stem cells in regenerative medicine.

Dr. Hematti’s laboratory research focuses on immunobiology of stem cell transplantation with a special focus on investigating the immunomodulatory and anti-inflammatory properties of macrophages. Dr. Hematti has several issued and filed patents in the field of macrophage cell therapy. Dr. Hematti with Drs. John Kink, Eric Schmuck and Amish Raval received the 2017 Innovaion fo the year award from WARF for their discovery of developing therapeutic cells for tissue-specific repair. Dr. Hematti is collaborating with many investigators on the UW-campus studying the potential of cellular therapy in many different pre-clinical models with the goal of translating those discoveries into early phase clinical trials.

Selected References:
  • Bouchlaka MN, Moffitt AB, Kim J, Kink JA, Bloom DD, Love C, Dave S, Hematti P, Capitini CM., Human Mesenchymal Stem Cell-Educated Macrophages Are a Distinct High IL-6-Producing Subset that Confer Protection in Graft-versus-Host-Disease and Radiation Injury Models. Biol Blood Marrow Transplant. 2017 Feb 28. pii: S1083-8791(17)30306-3. doi: 10.1016/j.bbmt.2017.02.018. Epub 2017 Feb 28. PMID: 28257800
  • Muir P, Hans EC, Racette M, Volstad N, Sample SJ, Heaton C, Holzman G, Schaefer SL, Bloom DD, Bleedorn JA, Hao Z, Amene E, Suresh M, Hematti P., Autologous Bone Marrow-Derived Mesenchymal Stem Cells Modulate Molecular Markers of Inflammation in Dogs with Cruciate Ligament Rupture. PLoS One. 2016 Aug 30;11(8):e0159095. doi: 10.1371/journal.pone.0159095. eCollection 2016. PMID: 27575050
  • Bloom DD, Centanni JM, Bhatia N, Emler CA, Drier D, Leverson GE, McKenna DH Jr, Gee AP, Lindblad R, Hei DJ, Hematti P., Areproducible immunopotency assay to measure mesenchymal stromal cell-mediated T-cell suppression. Cytotherapy. 2015 Feb;17(2):140-51. doi: 10.1016/j.jcyt.2014.10.002. Epub 2014 Nov 21. PMID: 25455739
  • Raval AN, Schmuck EG, Tefera G, Leitzke C, Ark CV, Hei D, Centanni JM, de Silva R, Koch J, Chappell RG, Hematti P., Bilateral administration of autologous CD133+ cells in ambulatory patients with refractory critical limb ischemia: lessons learned from a pilot randomized, double-blind, placebo-controlled trial. Cytotherapy. 2014 Dec;16(12):1720-32. doi: 10.1016/j.jcyt.2014.07.011. Epub 2014 Sep 18. PMID: 25239491
  • Kim J, Hematti P., Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol. 2009 Dec;37(12):1445-53. doi: 10.1016/j.exphem.2009.09.004. Epub 2009 Sep 20. PMID: 19772890